Glenmark Pharmaceuticals Ltd.

₹2,331

-3.7 (-0.2%)

GLENMARK Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 65,936.1 Cr

P/E Ratio48.3

Dividend Yield0.11 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,362.58	Bearish
10-DMA	2,407.71	Bearish
20-DMA	2,418.33	Bearish
50-DMA	2,353.89	Bearish
100-DMA	2,296.77	Bullish
200-DMA	2,200.44	Bullish

Historical Performance

1 Year

19%

3 Years

172.5%

5 Years

354.3%

10 Years

152.4%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	1,69,825	1,33,217	1,18,131	1,15,832	1,23,049
Total Expenditure	1,24,101	1,09,704	1,06,178	99,482	99,846
Other Income	4,606	1,137	8,400	2,889	1,667
Operating Profit	50,330	24,651	20,353	19,239	24,870
Interest	2,087	2,071	5,160	3,490	2,981
Depreciation	5,735	4,860	5,819	5,692	4,867
Profit Before Tax	19,847	13,992	365	2,398	14,412
Consolidated Net Profit	13,619	10,471	-15,017	2,972	9,417
Adjusted EPS	48	37	-53	11	33

Compounded Sales Growth

10 Years:17.3

5 Years:9.2

3 Years:8

TTM:5

Compounded Profit Growth

10 Years:12.9

5 Years:7

3 Years:35.6

TTM:5.4

Stock Price CAGR

10 Years:9.7

5 Years:35.4

3 Years:40.4

TTM:17.7

Return on Equity

10 Years:39.3

5 Years:33.4

3 Years:-53.2

last year:48.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	282	282	282	282	282
Total Reserves	1,04,499	88,122	78,015	94,281	90,421
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	17,730	1,094	-3,572	26,214	12,696
Other Current Liabilities	14,679	4,362	15,172	16,053	14,463
Short Term Borrowings	---	16,815	8,334	3,500	3,700
Total Liabilities	1,86,613	1,49,254	1,33,089	1,75,658	1,53,972
Capital Work in Progress	4,279	5,420	4,193	10,658	9,211
Long Term Loans & Advances	4,927	2,427	2,117	1,808	1,614
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	14,209	10,748	12,190	9,079	9,724
Total Current Assets	1,12,997	92,955	74,281	84,236	82,823
Total Assets	1,86,613	1,49,254	1,33,089	1,75,658	1,53,972
Adjusted Book Value	371	313	277	335	321

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 48.3, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 40.4%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹50330 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹169825 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1177153.8

No. of Shares: 505 (Approx)

Performance:17.7%

177153.8

NIFTY Performance: -9.9%

1 day Top Gainers